Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072

Benson, Charlotte; Ray‐Coquard, Isabelle; Sleijfer, Stefan; Litière, Saskia; Blay, Jean‐Yves; Cesne, Axel Le; Pápai, Zsuzsa; Judson, Ian; Schöffski, Patrick; Chawla, Sant P.; Gil, Thierry; Piperno‐Neumann, Sophie; Marréaud, Sandrine; Dewji, M.R.; Graaf, Winette T.A. van der

doi:10.1016/j.ygyno.2016.03.024

Cited by 59 publications

(48 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 47 A subsequent analysis of patients with uterine sarcoma in the PALETTE trial showed similar response rates to the overall population. 48 …”

Section: Advanced Diseasementioning

confidence: 99%

Uterine sarcoma – current perspectives

Benson

Miah²

2017

IJWH

View full text Add to dashboard Cite

Uterine sarcomas comprise a group of rare tumors with differing tumor biology, natural history and response to treatment. Diagnosis is often made following surgery for presumed benign disease. Currently, preoperative imaging does not reliably distinguish between benign leiomyomas and other malignant pathology. Uterine leiomyosarcoma is the most common sarcoma, but other subtypes include endometrial stromal sarcoma (low grade and high grade), undifferentiated uterine sarcoma and adenosarcoma. Clinical trials have shown no definite survival benefit of adjuvant radiotherapy or chemotherapy and have been hampered by the rarity and heterogeneity of these disease types. There is a role of adjuvant treatment in carefully selected cases following multidisciplinary discussion at sarcoma reference centers. In patients with metastatic disease, systemic chemotherapy can then be considered. There is activity of a number of agents, including doxorubicin, trabectedin, gemcitabine-based chemotherapy, eribulin and pazopanib. Patients should be considered for clinical trial entry where possible. Close international collaboration is important to allow progress in this group of diseases.

show abstract

“… 47 A subsequent analysis of patients with uterine sarcoma in the PALETTE trial showed similar response rates to the overall population. 48 …”

Section: Advanced Diseasementioning

confidence: 99%

Uterine sarcoma – current perspectives

Benson

Miah²

2017

IJWH

View full text Add to dashboard Cite

show abstract

“…Median PFS was 3.0 months (95% confidence interval [CI] 2.5–4.7) in uterine versus 4.5 (95% CI 3.7–5.1) in nonuterine STS. Median OS was 17.5 months (95% CI 11.1–19.6), which was longer than the nonuterine population OS of 11.1 months (95% CI 10.2–12.0; p = .352) .…”

Section: Single Agents In Metastatic Ulmsmentioning

confidence: 99%

Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm

et al. 2018

View full text Add to dashboard Cite

Recent regulatory approval of novel treatment options has significantly expanded the therapeutic armamentarium, and the addition of these therapies has challenged clinicians to select and optimally sequence these compounds. This review will focus on examination of current guidelines and consensus building for optimal sequencing of systemic therapies for advanced or recurrent uterine leoimyosarcoma.

show abstract

“…Several reports have recently demonstrated that new-generation anticancer agents, including bevacizumab, pazopanib, eribulin and trabectedin, are effective for recurrent LMS (18)(19)(20)(21). Comparison of SCS with these treatments could be useful.…”

Section: Scs -----------------------------------------mentioning

confidence: 99%

Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas

et al. 2018

View full text Add to dashboard Cite

Abstract. Uterine sarcomas are some of the most malignant and aggressive tumor types among the gynecologic malignancies, and they are associated with a high rate of recurrence and a poor prognosis. Due to their rarity and diversity, the optimal treatment for recurrent uterine sarcomas has not yet been elucidated. The aim of the present study was to investigate the potential of secondary cytoreductive surgery (SCS) for patients with recurrent uterine sarcomas. A total of 18 patients with recurrent uterine sarcomas were retrospectively identified at the

show abstract

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072

Cited by 59 publications

References 27 publications

Uterine sarcoma – current perspectives

Uterine sarcoma – current perspectives

Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm

Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas

Contact Info

Product

Resources

About

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072

Cited by 59 publications

References 27 publications

Uterine sarcoma &ndash; current perspectives

Uterine sarcoma &ndash; current perspectives

Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm

Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas

Contact Info

Product

Resources

About

Uterine sarcoma – current perspectives

Uterine sarcoma – current perspectives